Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will post earnings per share of ($2.48) for the year, down from their previous estimate of ($1.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.94) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at $0.49 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 EPS.
Check Out Our Latest Research Report on ALNY
Alnylam Pharmaceuticals Trading Up 1.2 %
ALNY opened at $278.76 on Thursday. The stock has a market capitalization of $35.95 billion, a P/E ratio of -106.40 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The firm’s fifty day simple moving average is $247.13 and its 200 day simple moving average is $260.26.
Insider Transactions at Alnylam Pharmaceuticals
In related news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,372 shares of company stock valued at $5,634,205. Company insiders own 1.50% of the company’s stock.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the business. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $61,160,000. Eventide Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after buying an additional 130,482 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $29,111,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Basic Materials Stocks Investing
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How Investors Can Find the Best Cheap Dividend Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.